


Corrigendum

doi: 10.1111/j.1432-2277.2011.01385.x

In [1], the authors regret that Figures 2a and 2b were inadvertently transposed in this article. The previous Figure 2b in fact shows Time to primary endpoint, while the previous Figure 2a shows Freedom from first BPAR.

The authors and publisher would like to apologise for this error. The figures should have appeared as shown below:



Reference

1. Dantal J, Berthoux F, Moal M-C, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle J-P, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E and on behalf of the RAD A2420 Study Group. Efficacy and safety of *de novo* or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. *Transplant International* 2010; **23**: 1084–1093. doi: 10.1111/j.1432-2277.2010.01094.x